QPS, a prominent global contract research organization (CRO), has announced the expansion of its laboratory services, reinforcing its capabilities in clinical trials and cell therapy development.
The newly enhanced facilities, strategically located in Springfield, Missouri, include a central laboratory for sample analysis, a leukoplakia cell therapy production unit, and expanded peripheral blood mononuclear cell (PBMC) capabilities. These additions not only bolster QPS’s existing bioanalysis, translational medicine, and PBMC laboratories across its global network but also provide [specific benefits] to the pharmaceutical and biotechnology industries.
The central laboratory, equipped with advanced technologies for chemistry, urinalysis, serology, coagulation, and haematology testing, is a cornerstone of our commitment to subject safety during clinical trials. It operates alongside a dedicated safety laboratory and a self-contained pharmacy, providing comprehensive support for clinical trial operations and ensuring the highest standards of safety and efficiency.
QPS has established a state-of-the-art leukoplakia collection and processing facility in response to the burgeoning demand for cell therapy products. This facility addresses the increasing need for blood products crucial to cell therapy research, supported by a substantial database of potential blood donors among its 35,000 study participants.
Benjamin Chien, Chairman, President, and CEO of QPS, underscored the strategic importance of these expansions amidst a growing market for cell and gene therapy programs. With over 3,000 active programs and a projected CAGR exceeding 8% in the coming years, the demand for leukoplakia products is poised for significant growth. These expansions are a clear manifestation of QPS’s vision and direction in the industry.
Additionally, QPS has expanded its PBMC services with a new processing lab in Springfield. This new facility complements the existing one in Miami, Florida, by [specific complementary aspect], addressing regional demand for PBMC processing, which is crucial in vaccine trials and best conducted near clinical trial units.
Brendon Bourg, Vice President of Early Phase Clinical and Head of Administration at QPS Missouri, emphasized that these expansions strengthen QPS’s position as a comprehensive provider of clinical research services. The new facilities integrate seamlessly with QPS’s existing capabilities, including a 240-bed clinical trials unit and clinical trial kit production facility.
The developments underscore QPS’s unwavering commitment to meeting the evolving needs of the pharmaceutical and biotechnology industries. By positioning itself as a pivotal partner in advancing innovative therapies through robust research and development capabilities, QPS is demonstrating its adaptability and reliability in a rapidly changing industry.
